“…10 (sunitinib), 15 11 (sorafenib), 16 12 (pazopanib), 17 and 13 (vandetanib) 18 (Figure 2), undesired side effects such as hypertension and bleeding have been reported. [19][20][21] Recently, medicinal chemists tend to develop more selective FGFR inhibitors, and several orally available FGFR selective inhibitors have been reported to enter clinical trials, for example, 4 (NVP-BGJ398), 22 5 (AZD4547), 23 6 (CH5183284), 24 and 7 (LY2874455) 25 (Figure 1). The 3,5-dimethoxy-phenyl moiety of 4 and 5 occupies the same hydrophobic pocket and forms a hydrogen bond with Asp641, which is identified by 8 (PD173074) to contribute to their selectivity for FGFR1; [26][27] similar interactions are also observed between 6 and FGFR1.…”